Page 124 - ASHG 2013 Program Guide

INVITED AND PLATFORM SESSIONS  
 111
Taking photographs or sound recordings in all meeting rooms is strictly prohibited. Thank you for your cooperation.
INVITED AND PLATFORM SESSIONS
Friday, October 25
8:00
AM
–10:15
AM
Concurrent Platform (abstract-driven)
Session D (45-53)
SESSION 52 – New Frontiers in Pharmacogenetics
Grand Ballroom AB, Concourse Level, Westin Boston
Waterfront Hotel
Moderators
:
Joshua Lewis, Univ. of Maryland,
Baltimore; Eileen Dolan, Univ. of Chicago
313
/8:00
A genome-wide meta-analysis of the
response to inhaled bronchodilators among
subjects with chronic obstructive pulmonary
disease.
M. Hardin, M. H. Cho, M. McDonald, E.
Wan, D. A. Lomas, H. O. Coxson, L. D. Edwards,
W. MacNee, J. Vestbo, J. C. Yates, A. Agusti, P.
Calverley, B. Celli, C. Crim, S. Rennard, E. Wouters,
P. Bakke, E. A. Regan, B. Make, A. Litonjua, J. E.
Hokanson, J. D. Crapo, T. H. Beaty, E. K. Silberman,
C. P. Hersh, ECLIPSE and COPDGene Investigators.
314
/8:15
Genome-wide association study of opioid-
induced vomiting in the 23andMe cohort.
J. L.
Mountain, N. Eriksson, J. Y. Tung, A. S. Shmygelska,
H. L. McLoed, U. Francke, A. K. Kiefer, D. A. Hinds.
315
/8:30
Transcriptome profiling of human
airway smooth muscle cells stimulated with
dexamethasone identifies
CRISPLD2
as a regulator
of steroid and immune response.
B. E. Himes, X.
Jiang, P. Wagner, R. Hu, B. Klanderman, Q. Duan, J.
Lasky-Su, C. Nikolos, W. Jester, M. Johnson, R. A.
Panettieri, Jr., K. G. Tantisira, S. T. Weiss, Q. Lu.
316
/8:45
Potential of integrating human genetics
and electronic medical records for drug discovery:
The example of
TYK2
and rheumatoid arthritis.
D.
Diogo, K. P. Liao, R. S. Fulton, R. R. Graham, J. Cui,
J. C. Denny, T. Behrens, M. F. Seldin, P. K. Gregersen,
E. Mardis, R. M. Plenge, The RACI, i2b2-Rheumatoid
Arthritis, CORRONA.
317
/9:00
Rare variants contribute to bronchodilator
drug response in Latino children with asthma.
D. G.
Torgerson, K. A. Drake, C. R. Gignoux, J. M. Galanter,
L. A. Roth, S. Huntsman, D. Hu, C. Eng, S. W. Yee, L.
Lin, C. D. Campbell, E. E. Eichler, R. D. Hernandez, K.
M. Giacomini, E. G. Burchard, GALA II Investigators.
318
/9:15
Characterization of statin dose-response
within electronic medical records.
W. Q. Wei, Q. P.
Feng, L. Jiang, M. S. Waitara, O. F. Iwuchukwu, D. M.
Roden, M. Jiang, H. Xu, R. M. Krauss, J. I. Rotter, D.
A. Nickerson, R. L. Davis, R. L. Berg, P. L. Peissig, C.
A. McCarty, R. A. Wilke, J. C. Denny.
319
/9:30
Genome-wide analysis of creatine kinase
levels in statin-users.
M. P. Dubé, R. Zetler, Y.
Feroz Zada, V. Normand, I. Mongrain, N. Laplante,
A. Barhdadi, G. Asselin, S. Provost, J. D. Rioux, S.
deDenus, E. Kritikou, J. Turgeon, M. S. Phillips, J. C.
Tardif.
320
/9:45
The return of pharmacogenomic variants
in the MedSeq Project: Reporting approach and
physician response.
J. B. Krier, H. M. McLaughlin,
W. J. Lane, D. Metterville, I. Leshchiner, J. L. Vassy, C.
MacRae, M. S. Lebo, D. Lautenbach, R. C. Green, H.
L. Rehm.
321
/10:00
Genetic evidence improves chances of
drug discovery success.
M. R. Nelson, H. Tipney, J.
L. Painter, J. Shen, P. Nicoletti, Y. Shen, A. Floratos,
P. C. Sham, M. J. Li, J. Wang, P. Agarwal, J. C.
Whittaker, P. Sanseau.